Skip to main content
. 2020 Dec 4;12(12):3633. doi: 10.3390/cancers12123633

Figure 1.

Figure 1

Colorimetric representation of RAS and methylation status in plasma samples from colorectal cancer patients at baseline (T0), after 4 months of first-line therapy (T1), at the time of first progressive disease (PD) (T2), and at the time of second PD (T3).